{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:38:12Z","timestamp":1769582292539,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K12732"],"award-info":[{"award-number":["25K12732"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10147-025-02942-8","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T20:39:51Z","timestamp":1766435991000},"page":"310-318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term progression-free survivors (\u201csuper responders\u201d) to olaparib maintenance in recurrent ovarian cancer: a multicenter real-world study (KCOG-G2101s)"],"prefix":"10.1007","volume":"31","author":[{"given":"Naho","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9994-2131","authenticated-orcid":false,"given":"Hidekatsu","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimihiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roze","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tsubamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoe","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Katsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Kai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Morii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriomi","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"2942_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10147-024-02473-8","volume":"29","author":"H Nakai","year":"2024","unstructured":"Nakai H, Higashi T, Kakuwa T et al (2024) Trends in gynecologic cancer in Japan: incidence from 1980 to 2019 and mortality from 1981 to 2021. Int J Clin Oncol 29:363\u2013371. https:\/\/doi.org\/10.1007\/s10147-024-02473-8","journal-title":"Int J Clin Oncol"},{"key":"2942_CR2","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.3802\/jgo.2022.33.e83","volume":"33","author":"I Konishi","year":"2022","unstructured":"Konishi I, Abiko K, Hayashi T et al (2022) Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics. J Gynecol Oncol 33:e83. https:\/\/doi.org\/10.3802\/jgo.2022.33.e83","journal-title":"J Gynecol Oncol"},{"key":"2942_CR3","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1111\/cas.15747","volume":"114","author":"K Yoshihara","year":"2023","unstructured":"Yoshihara K, Baba T, Tokunaga H et al (2023) Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 study. Cancer Sci 114:2515\u20132523. https:\/\/doi.org\/10.1111\/cas.15747","journal-title":"Cancer Sci"},{"key":"2942_CR4","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/s41416-022-02122-9","volume":"128","author":"S Takamatsu","year":"2023","unstructured":"Takamatsu S, Yoshihara K, Baba T et al (2023) Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study. Br J Cancer 128:1095\u20131104. https:\/\/doi.org\/10.1038\/s41416-022-02122-9","journal-title":"Br J Cancer"},{"key":"2942_CR5","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10147-022-02163-3","volume":"27","author":"H Nakai","year":"2022","unstructured":"Nakai H, Matsumura N (2022) Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs. Int J Clin Oncol 27:1001\u20131012. https:\/\/doi.org\/10.1007\/s10147-022-02163-3","journal-title":"Int J Clin Oncol"},{"key":"2942_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/934261","author":"M Koshiyama","year":"2014","unstructured":"Koshiyama M, Matsumura N, Konishi I (2014) Recent concepts of ovarian carcinogenesis: type I and type II. BioMed Res Int. https:\/\/doi.org\/10.1155\/2014\/934261","journal-title":"BioMed Res Int"},{"key":"2942_CR7","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/s41416-021-01560-1","volume":"125","author":"SE Willis","year":"2021","unstructured":"Willis SE, Winkler C, Roudier MP et al (2021) Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. Br J Cancer 125:1666\u20131676. https:\/\/doi.org\/10.1038\/s41416-021-01560-1","journal-title":"Br J Cancer"},{"key":"2942_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/14737159.2025.2485212","volume":"25","author":"H Takaya","year":"2025","unstructured":"Takaya H, Takamatsu S, Nakai H et al (2025) Homologous recombination deficiency: a reliable biomarker or a misleading indicator? Expert Rev Mol Diagn 25:199\u2013201. https:\/\/doi.org\/10.1080\/14737159.2025.2485212","journal-title":"Expert Rev Mol Diagn"},{"key":"2942_CR9","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1105535","journal-title":"N Engl J Med"},{"key":"2942_CR10","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J et al (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154\u20132164. https:\/\/doi.org\/10.1056\/NEJMoa1611310","journal-title":"N Engl J Med"},{"key":"2942_CR11","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D et al (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:1949\u20131961. https:\/\/doi.org\/10.1016\/S0140-6736(17)32440-6","journal-title":"Lancet"},{"key":"2942_CR12","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","volume":"17","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Harter P, Gourley C et al (2016) Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 17:1579\u20131589. https:\/\/doi.org\/10.1016\/S1470-2045(16)30376-X","journal-title":"Lancet Oncol"},{"key":"2942_CR13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2025.03.018","volume":"195","author":"UA Matulonis","year":"2025","unstructured":"Matulonis UA, Herrstedt J, Oza A et al (2025) ENGOT-OV16\/NOVA trial of niraparib in recurrent ovarian cancer: survival and long-term safety. Gynecol Oncol 195:192\u2013199. https:\/\/doi.org\/10.1016\/j.ygyno.2025.03.018","journal-title":"Gynecol Oncol"},{"key":"2942_CR14","doi-asserted-by":"publisher","first-page":"115584","DOI":"10.1016\/j.ejca.2025.115584","volume":"225","author":"JA Ledermann","year":"2025","unstructured":"Ledermann JA, Oza AM, Lorusso D et al (2025) Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: final results of the phase 3, randomized, placebo-controlled ARIEL3 trial. Eur J Cancer 225:115584. https:\/\/doi.org\/10.1016\/j.ejca.2025.115584","journal-title":"Eur J Cancer"},{"key":"2942_CR15","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","volume":"119","author":"M Friedlander","year":"2018","unstructured":"Friedlander M, Matulonis U, Gourley C et al (2018) Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 119:1075\u20131085. https:\/\/doi.org\/10.1038\/s41416-018-0271-y","journal-title":"Br J Cancer"},{"issue":"3","key":"2942_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ygyno.2022.08.021","volume":"167","author":"DM O'Malley","year":"2022","unstructured":"O\u2019Malley DM, Oza AM, Lorusso D et al (2022) Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. Gynecol Oncol 167(3):404\u2013413. https:\/\/doi.org\/10.1016\/j.ygyno.2022.08.021","journal-title":"Gynecol Oncol"},{"key":"2942_CR17","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.3802\/jgo.2025.36.e47","volume":"36","author":"M Abe","year":"2025","unstructured":"Abe M, Hashimoto H, Soejima A et al (2025) Shared decision-making in patients with gynecological cancer and healthcare professionals: a cross-sectional observational study in Japan. J Gynecol Oncol 36:e47. https:\/\/doi.org\/10.3802\/jgo.2025.36.e47","journal-title":"J Gynecol Oncol"},{"issue":"12 Pt 1","key":"2942_CR18","first-page":"6523","volume":"45","author":"E Frei 3rd","year":"1985","unstructured":"Frei E 3rd (1985) Curative cancer chemotherapy. Cancer Res 45(12 Pt 1):6523\u20136537","journal-title":"Cancer Res"},{"issue":"12","key":"2942_CR19","doi-asserted-by":"publisher","first-page":"e1007752","DOI":"10.1371\/journal.pgen.1007752","volume":"14","author":"MS Cline","year":"2018","unstructured":"Cline MS, Liao RG, Parsons MT et al (2018) BRCA challenge: BRCA exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet 14(12):e1007752. https:\/\/doi.org\/10.1371\/journal.pgen.1007752","journal-title":"PLoS Genet"},{"key":"2942_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41416-021-01364-3","volume":"125","author":"T Takashima","year":"2021","unstructured":"Takashima T, Taniyama D, Sakamoto N et al (2021) Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers. Br J Cancer 125:65\u201377. https:\/\/doi.org\/10.1038\/s41416-021-01364-3","journal-title":"Br J Cancer"},{"key":"2942_CR21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00428-020-02840-6","volume":"478","author":"T Takashima","year":"2021","unstructured":"Takashima T, Sakamoto N, Murai J et al (2021) Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq. Virchows Arch 478:569\u2013579. https:\/\/doi.org\/10.1007\/s00428-020-02840-6","journal-title":"Virchows Arch"},{"key":"2942_CR22","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/s41416-024-02837-x","volume":"131","author":"S Takamatsu","year":"2024","unstructured":"Takamatsu S, Hillman RT, Yoshihara K et al (2024) Molecular classification of ovarian high-grade serous\/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study. Br J Cancer 131:1340\u20131349. https:\/\/doi.org\/10.1038\/s41416-024-02837-x","journal-title":"Br J Cancer"},{"key":"2942_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/cas.15518","volume":"114","author":"K Oda","year":"2023","unstructured":"Oda K, Aoki D, Tsuda H et al (2023) Japanese nationwide observational multicenter study of tumor BRCA1\/2 variant testing in advanced ovarian cancer. Cancer Sci 114:271\u2013280. https:\/\/doi.org\/10.1111\/cas.15518","journal-title":"Cancer Sci"},{"key":"2942_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","volume":"147","author":"AM Oza","year":"2017","unstructured":"Oza AM, Tinker AV, Oaknin A et al (2017) Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol 147:267\u2013275. https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.022","journal-title":"Gynecol Oncol"},{"key":"2942_CR25","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","volume":"28","author":"PC Fong","year":"2010","unstructured":"Fong PC, Yap TA, Boss DS et al (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512\u20139. https:\/\/doi.org\/10.1200\/JCO.2009.26.9589","journal-title":"J Clin Oncol"},{"key":"2942_CR26","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore KN, Secord AA, Geller MA et al (2019) Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 20:636\u2013648. https:\/\/doi.org\/10.1016\/S1470-2045(19)30029-4","journal-title":"Lancet Oncol"},{"key":"2942_CR27","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1038\/s41467-021-22582-6","volume":"12","author":"EM Swisher","year":"2021","unstructured":"Swisher EM, Kwan TT, Oza AM et al (2021) Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun 12:2487. https:\/\/doi.org\/10.1038\/s41467-021-22582-6","journal-title":"Nat Commun"},{"key":"2942_CR28","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1080\/14656566.2023.2295393","volume":"24","author":"H Nakai","year":"2023","unstructured":"Nakai H, Matsumura N (2023) Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics. Expert Opin Pharmacother 24:2161\u20132173. https:\/\/doi.org\/10.1080\/14656566.2023.2295393","journal-title":"Expert Opin Pharmacother"},{"key":"2942_CR29","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1007\/s10147-022-02169-x","volume":"27","author":"H Nakai","year":"2022","unstructured":"Nakai H, Matsumura N (2022) The roles and limitations of bevacizumab in the treatment of ovarian cancer. Int J Clin Oncol 27:1120\u20131126. https:\/\/doi.org\/10.1007\/s10147-022-02169-x","journal-title":"Int J Clin Oncol"},{"key":"2942_CR30","doi-asserted-by":"publisher","first-page":"e2326834","DOI":"10.1001\/jamanetworkopen.2023.26834","volume":"6","author":"S Takamatsu","year":"2023","unstructured":"Takamatsu S, Nakai H, Yamaguchi K et al (2023) Time-dependent changes in risk of progression during use of bevacizumab for ovarian cancer. JAMA Netw Open 6:e2326834. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.26834","journal-title":"JAMA Netw Open"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02942-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02942-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02942-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T04:08:05Z","timestamp":1769486885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02942-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2942"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02942-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N Matsumura received lecture fees from AstraZeneca, MSD, and Takeda Pharmaceutical, as well as a research grant from AstraZeneca. N Matsumura is also an outside director of Takara Bio. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}